Jounce Therapeutics Stock Price, News & Analysis (NASDAQ:JNCE)

$15.33 -0.04 (-0.26 %)
(As of 11/24/2017 06:34 AM ET)
Previous Close$15.37
Today's Range$15.15 - $15.65
52-Week Range$11.05 - $29.29
Volume57,984 shs
Average Volume137,842 shs
Market Capitalization$495.62 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Jounce Therapeutics (NASDAQ:JNCE)

Jounce Therapeutics logoJounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. The Company's lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates Inducible T cell CO-Stimulator (ICOS) and is in a Phase II trial.

Receive JNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:JNCE
CUSIPN/A
Phone857-259-3840

Debt

Debt-to-Equity RatioN/A
Current Ratio4.13%
Quick Ratio4.13%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$37.20 million
Price / Sales13.29
Cash FlowN/A
Price / CashN/A
Book Value$5.43 per share
Price / Book2.82

Profitability

Trailing EPS($0.21)
Net Income$-13,700,000.00
Net Margins-2.03%
Return on Equity-1.39%
Return on Assets-0.50%

Miscellaneous

Employees85
Outstanding Shares32,250,000

Frequently Asked Questions for Jounce Therapeutics (NASDAQ:JNCE)

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics, Inc. (NASDAQ:JNCE) released its quarterly earnings results on Monday, November, 13th. The company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.12. The business had revenue of $18.10 million for the quarter, compared to the consensus estimate of $20 million. Jounce Therapeutics had a negative net margin of 2.03% and a negative return on equity of 1.39%. The firm's revenue was up 7.1% compared to the same quarter last year. View Jounce Therapeutics' Earnings History.

Where is Jounce Therapeutics' stock going? Where will Jounce Therapeutics' stock price be in 2017?

4 brokerages have issued 12-month price objectives for Jounce Therapeutics' stock. Their predictions range from $28.00 to $30.00. On average, they expect Jounce Therapeutics' stock price to reach $29.00 in the next year. View Analyst Ratings for Jounce Therapeutics.

What are Wall Street analysts saying about Jounce Therapeutics stock?

Here are some recent quotes from research analysts about Jounce Therapeutics stock:

  • 1. According to Zacks Investment Research, "Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States. " (11/15/2017)
  • 2. Cowen Inc analysts commented, "Jounce provided an interim update from the ICONIC trial." (6/9/2017)

Who are some of Jounce Therapeutics' key competitors?

Who are Jounce Therapeutics' key executives?

Jounce Therapeutics' management team includes the folowing people:

  • Perry Karsen, Chairman of the Board (Age 62)
  • Richard Murray Ph.D., President, Chief Executive Officer, Director (Age 58)
  • James P. Allison Ph.D., Co-Founder
  • Thomas F. Gajewski M.D. Ph.D., Co-Founder
  • Drew Pardoll M.D. Ph.D., Co-Founder
  • Padmanee Sharma M.D. Ph.D., Co-Founder
  • Kimberlee Cobleigh Drapkin CPA, Chief Financial Officer, Treasurer (Age 49)
  • Deborah Law, Chief Scientific Officer
  • Elizabeth G. Trehu M.D., Chief Medical Officer (Age 56)
  • Luis A. Diaz Jr. M.D., Director

When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Who owns Jounce Therapeutics stock?

Jounce Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Brown Advisory Inc. (1.48%), Fosun International Ltd (0.89%), Alyeska Investment Group L.P. (0.81%), Artal Group S.A. (0.62%), Ameriprise Financial Inc. (0.57%) and Conning Inc. (0.39%). Company insiders that own Jounce Therapeutics stock include Celgene Switzerland Llc and John Duncan Higgons. View Institutional Ownership Trends for Jounce Therapeutics.

Who sold Jounce Therapeutics stock? Who is selling Jounce Therapeutics stock?

Jounce Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A.. View Insider Buying and Selling for Jounce Therapeutics.

Who bought Jounce Therapeutics stock? Who is buying Jounce Therapeutics stock?

Jounce Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Fosun International Ltd, Brown Advisory Inc., Alyeska Investment Group L.P., Ameriprise Financial Inc., Parsons Capital Management Inc. RI, Conning Inc., Russell Investments Group Ltd. and First Manhattan Co.. Company insiders that have bought Jounce Therapeutics stock in the last two years include Celgene Switzerland Llc and John Duncan Higgons. View Insider Buying and Selling for Jounce Therapeutics.

How do I buy Jounce Therapeutics stock?

Shares of Jounce Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Jounce Therapeutics' stock price today?

One share of Jounce Therapeutics stock can currently be purchased for approximately $15.33.

How big of a company is Jounce Therapeutics?

Jounce Therapeutics has a market capitalization of $495.62 million and generates $37.20 million in revenue each year. The company earns $-13,700,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Jounce Therapeutics employs 85 workers across the globe.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.


MarketBeat Community Rating for Jounce Therapeutics (JNCE)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  72 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  119
MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Jounce Therapeutics (NASDAQ:JNCE)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.602.803.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.67$23.67$23.67$29.00
Price Target Upside: 67.49% upside44.66% upside90.55% upside16.75% upside

Consensus Price Target History for Jounce Therapeutics (NASDAQ:JNCE)

Price Target History for Jounce Therapeutics (NASDAQ:JNCE)

Analysts' Ratings History for Jounce Therapeutics (NASDAQ:JNCE)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/13/2017J P Morgan Chase & CoSet Price TargetBuy$28.00N/AView Rating Details
11/10/2017Robert W. BairdReiterated RatingBuy$30.00N/AView Rating Details
6/9/2017Cowen IncReiterated RatingBuyLowView Rating Details
2/21/2017Wells Fargo & CompanyInitiated CoverageOutperform -> OutperformN/AView Rating Details
(Data available from 11/25/2015 forward)

Earnings

Earnings History and Estimates Chart for Jounce Therapeutics (NASDAQ:JNCE)

Earnings by Quarter for Jounce Therapeutics (NASDAQ:JNCE)

Earnings History by Quarter for Jounce Therapeutics (NASDAQ JNCE)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017Q3 2017($0.25)($0.13)$20.00 million$18.10 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.15)($0.11)$19.94 million$20.29 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.09)($0.02)$19.71 million$20.30 millionViewN/AView Earnings Details
3/10/201712/31/2016$0.04$0.05$15.00 million$20.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Jounce Therapeutics (NASDAQ:JNCE)
Current Year EPS Consensus Estimate: $-0.77 EPS
Next Year EPS Consensus Estimate: $-1.37 EPS

Dividends

Dividend History for Jounce Therapeutics (NASDAQ:JNCE)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Jounce Therapeutics (NASDAQ JNCE)

Institutional Ownership Percentage: 40.95%
Insider Trades by Quarter for Jounce Therapeutics (NASDAQ:JNCE)
Insider Trades by Quarter for Jounce Therapeutics (NASDAQ:JNCE)

Insider Trades by Quarter for Jounce Therapeutics (NASDAQ JNCE)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/1/2017Celgene Switzerland LlcMajor ShareholderBuy625,000$16.00$10,000,000.00View SEC Filing  
2/1/2017John Duncan HiggonsDirectorBuy6,700$16.00$107,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Jounce Therapeutics (NASDAQ JNCE)

Source:
DateHeadline
Jounce Therapeutics, Inc. – Value Analysis (NASDAQ:JNCE) : November 24, 2017Jounce Therapeutics, Inc. – Value Analysis (NASDAQ:JNCE) : November 24, 2017
finance.yahoo.com - November 24 at 5:03 PM
Jounce Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : JNCE-US : November 23, 2017Jounce Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : JNCE-US : November 23, 2017
finance.yahoo.com - November 23 at 5:00 PM
Jounce Therapeutics, Inc. (JNCE) Expected to Post Earnings of -$0.49 Per ShareJounce Therapeutics, Inc. (JNCE) Expected to Post Earnings of -$0.49 Per Share
www.americanbankingnews.com - November 22 at 9:40 AM
Can This Tiny Biotech Stock Pay Off Big for Celgene?Can This Tiny Biotech Stock Pay Off Big for Celgene?
finance.yahoo.com - November 17 at 9:17 AM
Jounce Therapeutics, Inc. (JNCE) Posts Quarterly  Earnings Results, Beats Expectations By $0.12 EPSJounce Therapeutics, Inc. (JNCE) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPS
www.americanbankingnews.com - November 14 at 11:24 AM
Jounce Therapeutics, Inc. (JNCE) Q3 2017 Earnings Conference Call TranscriptJounce Therapeutics, Inc. (JNCE) Q3 2017 Earnings Conference Call Transcript
www.fool.com - November 13 at 12:58 PM
Jounce Therapeutics Reports Third Quarter 2017 Financial ResultsJounce Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 13 at 9:44 AM
Zacks: Jounce Therapeutics, Inc. (JNCE) Given Consensus Recommendation of "Strong Buy" by BrokeragesZacks: Jounce Therapeutics, Inc. (JNCE) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - November 11 at 3:28 PM
Jounce Therapeutics to Present at the Stifel 2017 Healthcare ConferenceJounce Therapeutics to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 11 at 2:44 PM
Jounce Therapeutics, Inc. (JNCE) Receives Buy Rating from Robert W. BairdJounce Therapeutics, Inc. (JNCE) Receives Buy Rating from Robert W. Baird
www.americanbankingnews.com - November 11 at 12:10 PM
Jounce Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual MeetingJounce Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
finance.yahoo.com - November 8 at 11:07 AM
Jounce Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday, November 13, 2017Jounce Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday, November 13, 2017
finance.yahoo.com - November 8 at 11:07 AM
Jounce Therapeutics, Inc. (JNCE) Expected to Post Quarterly Sales of $20.00 MillionJounce Therapeutics, Inc. (JNCE) Expected to Post Quarterly Sales of $20.00 Million
www.americanbankingnews.com - November 4 at 8:22 AM
-$0.25 EPS Expected for Jounce Therapeutics, Inc. (JNCE) This Quarter-$0.25 EPS Expected for Jounce Therapeutics, Inc. (JNCE) This Quarter
www.americanbankingnews.com - November 2 at 3:18 PM
Jounce Therapeutics Is Now Oversold (JNCE)Jounce Therapeutics Is Now Oversold (JNCE)
www.thestreet.com - October 26 at 3:17 PM
Jounce Therapeutics Appoints Luis A. Diaz, Jr., M.D., to its Board of DirectorsJounce Therapeutics Appoints Luis A. Diaz, Jr., M.D., to its Board of Directors
finance.yahoo.com - October 23 at 7:48 PM
Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : October 19, 2017Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : October 19, 2017
finance.yahoo.com - October 20 at 1:43 AM
Jounce Therapeutics, Inc. (JNCE) Expected to Announce Quarterly Sales of $20.00 MillionJounce Therapeutics, Inc. (JNCE) Expected to Announce Quarterly Sales of $20.00 Million
www.americanbankingnews.com - October 16 at 3:18 AM
Jounce Therapeutics, Inc. (JNCE) Stock Rating Reaffirmed by Robert W. BairdJounce Therapeutics, Inc. (JNCE) Stock Rating Reaffirmed by Robert W. Baird
www.americanbankingnews.com - September 18 at 5:08 PM
Jounce Therapeutics, Inc. (JNCE) Given "Buy" Rating at Robert W. BairdJounce Therapeutics, Inc. (JNCE) Given "Buy" Rating at Robert W. Baird
www.americanbankingnews.com - September 12 at 9:28 PM
 Analysts Anticipate Jounce Therapeutics, Inc. (JNCE) Will Post Quarterly Sales of $20.00 Million Analysts Anticipate Jounce Therapeutics, Inc. (JNCE) Will Post Quarterly Sales of $20.00 Million
www.americanbankingnews.com - September 9 at 7:00 PM
 Brokerages Expect Jounce Therapeutics, Inc. (JNCE) to Post -$0.25 EPS Brokerages Expect Jounce Therapeutics, Inc. (JNCE) to Post -$0.25 EPS
www.americanbankingnews.com - September 7 at 2:28 AM
Jounce Therapeutics to Present at Upcoming Investor Conferences in SeptemberJounce Therapeutics to Present at Upcoming Investor Conferences in September
finance.yahoo.com - August 31 at 6:30 AM
 Jounce Therapeutics, Inc. (JNCE) Given Average Rating of "Strong Buy" by Analysts Jounce Therapeutics, Inc. (JNCE) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - August 30 at 12:18 PM
Jounce Therapeutics, Inc. – Value Analysis (NASDAQ:JNCE) : August 29, 2017Jounce Therapeutics, Inc. – Value Analysis (NASDAQ:JNCE) : August 29, 2017
finance.yahoo.com - August 29 at 12:48 AM
$20.00 Million in Sales Expected for Jounce Therapeutics, Inc. (JNCE) This Quarter$20.00 Million in Sales Expected for Jounce Therapeutics, Inc. (JNCE) This Quarter
www.americanbankingnews.com - August 21 at 5:48 AM
Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : August 18, 2017Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : August 18, 2017
finance.yahoo.com - August 18 at 7:59 PM
Jounce Therapeutics (JNCE) Jumps: Stock Moves 7.4% HigherJounce Therapeutics (JNCE) Jumps: Stock Moves 7.4% Higher
finance.yahoo.com - August 18 at 6:07 AM
Jounce Therapeutics Names Hugh Cole as Chief Business Officer and Head of Corporate DevelopmentJounce Therapeutics Names Hugh Cole as Chief Business Officer and Head of Corporate Development
feeds.benzinga.com - August 15 at 8:40 AM
Jounce Therapeutics Reports Second Quarter 2017 Financial ResultsJounce Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 10:40 PM
Jounce Therapeutics, Inc. (JNCE) Issues  Earnings ResultsJounce Therapeutics, Inc. (JNCE) Issues Earnings Results
www.americanbankingnews.com - August 9 at 5:34 PM
Jounce Therapeutics to Announce Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, August 9, 2017Jounce Therapeutics to Announce Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, August 9, 2017
finance.yahoo.com - August 3 at 1:07 AM
 Jounce Therapeutics, Inc. (NASDAQ:JNCE) Given Consensus Recommendation of "Strong Buy" by Brokerages Jounce Therapeutics, Inc. (NASDAQ:JNCE) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - July 29 at 12:44 AM
Jounce Therapeutics, Inc.s Lock-Up Period Will Expire  on July 26th (NASDAQ:JNCE)Jounce Therapeutics, Inc.'s Lock-Up Period Will Expire on July 26th (NASDAQ:JNCE)
www.americanbankingnews.com - July 19 at 9:34 AM
Jounce Therapeutics, Inc. (JNCE) Expected to Announce Quarterly Sales of $20.15 MillionJounce Therapeutics, Inc. (JNCE) Expected to Announce Quarterly Sales of $20.15 Million
www.americanbankingnews.com - July 9 at 7:24 AM
Jounce Therapeutics, Inc. (NASDAQ:JNCE) Expected to Post Earnings of -$0.15 Per ShareJounce Therapeutics, Inc. (NASDAQ:JNCE) Expected to Post Earnings of -$0.15 Per Share
www.americanbankingnews.com - July 8 at 12:10 AM
4:03 pm Jounce Therapeutics will present preclinical data that support the ongoing Phase 1/2 ICONIC trial of JTX-2011 at the AACR Annual Meeting on April 34:03 pm Jounce Therapeutics will present preclinical data 'that support the ongoing Phase 1/2 ICONIC trial of JTX-2011' at the AACR Annual Meeting on April 3
us.rd.yahoo.com - March 23 at 6:40 PM
JOUNCE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andJOUNCE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
biz.yahoo.com - March 10 at 7:18 PM
Coverage initiated on Jounce Therapeutics by JP Morgan, Wells Fargo and Robert W. BairdCoverage initiated on Jounce Therapeutics by JP Morgan, Wells Fargo and Robert W. Baird
us.rd.yahoo.com - February 22 at 12:30 PM
IPO Stock News And Analysis: Find Today's Top New IssuesIPO Stock News And Analysis: Find Today's Top New Issues
us.rd.yahoo.com - February 9 at 7:00 PM

Social Media

Financials

Chart

Jounce Therapeutics (NASDAQ JNCE) Chart for Saturday, November, 25, 2017
Loading chart…

This page was last updated on 11/25/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.